Sun Pharmaceutical Industries has entered into an agreement to acquire around 37.76% equity shareholding of Ezerx Health Tech (EzeRx). Cost of acquisition will be Rs 28.69 crore. EzeRx is engaged in the production, marketing and distribution of non-invasive diagnostic and ancillary medical devices in and outside India.
Besides, the company has executed an additional agreement to acquire further around 4.04% equity shares in Agatsa Software (Agatsa) from existing shareholders resulting in total proposed acquisition of stake to go up to around 30.13% of Agatsa. Earlier, the company had acquired around 26.09% shares in Agatsa. Agatsa is engaged in research, development and commercialization of medical devices in the health diagnostics segment by leveraging technology and R&D capabilities.
Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: